2023-05-08 17:07:02 ET
- Atara Biotherapeutics press release ( NASDAQ: ATRA ): Q1 GAAP EPS of -$0.72 misses by $0.36 .
- Revenue of $1.23M (-83.2% Y/Y) misses by $29.45M .
- Cash, cash equivalents and short-term investments as of March 31, 2023, totaled $205.4 million, as compared to $242.8 million as of December 31, 2022
- Atara believes that its cash and investments as of March 31, 2023, will be sufficient to fund the Company’s planned operations into Q2 2024.
- Shares -7.41% AH.
For further details see:
Atara Biotherapeutics GAAP EPS of -$0.72 misses by $0.36, revenue of $1.23M misses by $29.45M